ArticleJournal for immunotherapy of cancer2026

Phase I trial of CJRB-101 plus pembrolizumab in patients with metastatic non-small cell lung cancer, head and neck squamous cell carcinoma and melanoma.

Jii Bum Lee et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.